Military veterans exemplify traits valuable to pharma industry.
Embracing business imperatives such as operational efficiency and a focus on a patient-centric approach can help pharma leaders provide a stable foundation amid lingering uncertainty.
Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.
2021‘s Pharmaceutical Industry Network Group (PING) conference focused on the UK’s COVID-19 response and how it can continue as a leader in science innovation and collaboration, including opportunities through use of health and genomic data.
Why pharma needs to focus on improving—not just extending life.
The current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
Delivering value-based care is expected to become even more prevalent, driven by factors such as patient comfort with digital tools and advancements in contractual arrangements.
Navigating the challenging landscape of pharmaceutical naming—where a name must meet regulatory approval, clear trademark hurdles, and capture market attention all at once.
Coordination of KOL engagement is all but impossible if the information an organization collects about them is fragmented. What is needed is a centralized database that captures all information about an expert from the multiple touch points across functions and geographies.
As therapeutics become more personalized and targeted, technology, such as open-source software, can help companies innovate.
Identifying unique traits in patients is key to creating the most effective support programs.
Knowing that product reimbursement affects performance and varies by geography, this article proposes the use of Reimbursement Benchmark Share (RBS) to quantify the influence of reimbursement on a product’s performance.
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
As the digital and social media revolution continues to evolve, healthcare marketers must consider how to unlock the full potential of social with innovative engagement opportunities.
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Pandemic-reinforced principles of successful drug launch.
Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
How one COVID-sparked model could help usher in needed reset.
The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and availability of novel medicines, and complex market dynamics.